Clinical trial
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
NCT00265551 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00265551 |
|---|---|
| Title | Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Olanzapine-Referenced, Parallel Group Safety, Efficacy, and Tolerability Study of SCA-136 in Subjects With Acute Exacerbations of Schizophrenia |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg), placebo |
| Enrollment | 300 |
| Start date | Jan 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Dec 14, 2005 |
| Last update posted | Dec 10, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: